Three peptides could be causing severe COVID-19 complications: proteolytic storm induces bradykinin disregulation

A study published in July 2020 hypothesized a link between the presence of bradykinin, a well-known peptide, and severe cases of COVID-19. Vardan Karamyan, Ph.D., an associate professor and vice chair for the Texas Tech University Health Sciences Center (TTUHSC) Jerry H. Hodge School of Pharmacy Department of Pharmaceutical Sciences, had not previously conducted or

Read More


A comprehensive guide to understand how SARS-CoV-2 enters the body and drugs that could mitigate infection

In the search for treatments for COVID-19, many researchers are focusing their attention on a specific protein that allows the virus to infect human cells. This protein, which cells carry on their surface, is called angiotensin converting enzyme 2 (ACE2) and provides the entry point for the coronavirus to enter cells. ACE2 is present in

Read More


COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year

COVID-19 is associated with a high incidence of thrombotic complications, which can be explained by the complex and unique interplay between coronaviruses and endothelial cells, the local and systemic inflammatory response, and the coagulation system. Empirically, an intensified dose of thrombosis prophylaxis is being used in patients admitted to hospital with COVID-19 and several guidelines

Read More


A Real-World Look at COVID-19 Vaccines Versus New Variants: NIH Director evaluation

Clinical trials have shown the COVID-19 vaccines now being administered around the country are highly effective in protecting fully vaccinated individuals from the coronavirus SARS-CoV-2. But will they continue to offer sufficient protection as the frequency of more transmissible and, in some cases, deadly emerging variants rise? More study and time is needed to fully

Read More


Covid-19: How can we keep the world’s doctors safe? An important paper by Fiona Godlee on The BMJ

The world’s doctors have been at the forefront of the pandemic response. Already overstretched by workforce shortages, they have carried exhaustion, uncertainty, and risk, redeploying to unfamiliar specialties, learning at speed, and adopting different ways of working and new technology, while all the time fearing for their patients, their families, and themselves. For many there has

Read More


In JAMA US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S J&J Vaccination, March 2 to April 21, 2021

Cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare and serious condition, has been described in Europe following receipt of the ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca), which uses a chimpanzee adenoviral vector. A mechanism similar to autoimmune heparin-induced thrombocytopenia (HIT) has been proposed. In the US, the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson), which uses a

Read More


Francis Crick Institute @The Crick researchers uncover a naturally occurring molecule that can help coronavirus escape antibodies

Researchers have found that a natural molecule can effectively block the binding of a subset of human antibodies to SARS-CoV-2. The discovery may help explain why some COVID-19 patients can become severely ill despite having high levels of antibodies against the virus. In their research, published in Science Advances today (22 April 2021), teams from the Francis

Read More


Successful treatment of vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT) with early steroids and IVIG.

Cases of unusual thrombosis and thrombocytopenia after administration of the ChAdOx1 nCoV‐19 vaccine (AstraZeneca) have been reported. The term vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT) was coined to reflect this new phenomenon.  In vitro experiments with VIPIT patient sera indicated that high dose intravenous immunoglobulins (IVIG) competitively inhibit the platelet activating properties of ChAdOx1 nCoV‐19 vaccine induced

Read More